Department of Radiation Oncology, Dana-Farber Cancer Institute, Children's Hospital, and Harvard Medical School, Boston, MA 02115, USA.
N Engl J Med. 2010 May 20;362(20):1909-19. doi: 10.1056/NEJMra0809889.
The study of rare genetic diseases can lead to insights into the cause and treatment of common diseases. An example is the rare chromosomal instability disorder, Fanconi Anemia (FA). Studies of this disease have elucidated general mechanisms of bone marrow failure, cancer pathogenesis, and resistance to chemotherapy. The principal features of FA are aplastic anemia in childhood, susceptibility to cancer or leukemia, and hypersensitivity of FA cells to DNA cross-linking agents. There are thirteen FA genes, and one of these genes is identical to the well known breast cancer susceptibility gene, . The corresponding FA proteins cooperate in the recognition and repair of damaged DNA. Inactivation of FA genes occurs not only in FA patients but also in a variety of cancers in the general population. These findings have broad implications for predicting the sensitivity and resistance of tumors to conventional anti-cancer agents, to inhibitors of poly-ADP ribose polymerase 1, an enzyme involved in DNA repair, and to other inhibitors of DNA repair.
对罕见遗传疾病的研究可以深入了解常见疾病的病因和治疗方法。例如,罕见的染色体不稳定性疾病范可尼贫血症(FA)。对这种疾病的研究阐明了骨髓衰竭、癌症发病机制和对化疗药物耐药的一般机制。FA 的主要特征是儿童期再生障碍性贫血、癌症或白血病易感性以及 FA 细胞对 DNA 交联剂的敏感性增加。FA 有十三个基因,其中一个基因与著名的乳腺癌易感基因 BRCA1 相同。相应的 FA 蛋白在识别和修复受损 DNA 方面发挥作用。FA 基因失活不仅发生在 FA 患者中,也发生在普通人群中的各种癌症中。这些发现对预测肿瘤对传统抗癌药物、多聚 ADP 核糖聚合酶 1 抑制剂(一种参与 DNA 修复的酶)以及其他 DNA 修复抑制剂的敏感性和耐药性具有广泛的意义。